Prime Medicine, a leading biotechnology company, announced the difficult decision to deprioritise its Chronic Granulomatous Disorder (CGD) PM359 prime editing programme for p47phox CGD. The programme is the next generation for gene therapies. Prime added that in addition to this strategic restructuring, the company had a cost and workforce reduction. 

The initial clinical data from our PM359 program for CGD has been very encouraging and clearly shows the potential of Prime Editing to make a meaningful difference in the lives of patients and families affected by CGD. Prime Medicine are actively exploring partnership opportunities with the goal of ensuring that PM359 can continue development.  

Prime Medicine shared a letter to the CGD community with a press release regarding this new, which you can find here.

Although this is disappointing news the CGD Society looks forward to any updates provided on the progression of this potentially life changing gene therapy.